Press Release

Category Added in a WPeMatico Campaign

MarketersMEDIA Newswire22 May 2026

Harsh Verma Publishes Nuanced Framework on Rise of Agentic AI and Enterprise System Era, Arguing AI System Architecture Has Replaced Model Building as the Core Discipline

Forbes Technology Council Member and Principal Software Engineer in AI, Harsh Verma, has set out his argument that the AI…
Read More »
MarketersMEDIA Newswire22 May 2026

Zycus Concludes Agentic AI Procurement Summit 2026; Forrester and Hackett Group Research Released

Zycus concluded the Agentic AI Procurement Summit 2026, a virtual event drawing 1,500+ procurement leaders from 50+ countries. The summit…
Read More »
Business Wire22 May 2026

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with…
Read More »
Business Wire22 May 2026

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with…
Read More »
Business Wire22 May 2026

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with…
Read More »
Business Wire22 May 2026

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs.…
Read More »
Business Wire22 May 2026

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs.…
Read More »
Business Wire22 May 2026

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs.…
Read More »
Business Wire22 May 2026

PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026

Two-year and post-hoc SURPASS-ET analyses highlight the impact of treatment timing, with durable responses and improved progression-free survival supporting consideration…
Read More »
Business Wire22 May 2026

ISG to Study UKG Pro Ecosystem Service Providers

Upcoming ISG Provider Lens® report will evaluate providers that modernize workforce operations with AI, data integration and continuous optimization STAMFORD,…
Read More »

Previous page Next page